488 related articles for article (PubMed ID: 23412334)
21. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
[TBL] [Abstract][Full Text] [Related]
22. Oncogene interference through targeting of chromatin regulators.
Roe JS; Vakoc CR
Cell Cycle; 2013 May; 12(10):1475-6. PubMed ID: 23624838
[No Abstract] [Full Text] [Related]
23. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z
J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074
[TBL] [Abstract][Full Text] [Related]
24. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.
Wang QF; Wu G; Mi S; He F; Wu J; Dong J; Luo RT; Mattison R; Kaberlein JJ; Prabhakar S; Ji H; Thirman MJ
Blood; 2011 Jun; 117(25):6895-905. PubMed ID: 21518926
[TBL] [Abstract][Full Text] [Related]
25. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
[TBL] [Abstract][Full Text] [Related]
26. Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia.
Barve A; Vega A; Shah PP; Ghare S; Casson L; Wunderlich M; Siskind LJ; Beverly LJ
Cells; 2019 Oct; 8(11):. PubMed ID: 31717699
[TBL] [Abstract][Full Text] [Related]
27. The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression.
Shema E; Tirosh I; Aylon Y; Huang J; Ye C; Moskovits N; Raver-Shapira N; Minsky N; Pirngruber J; Tarcic G; Hublarova P; Moyal L; Gana-Weisz M; Shiloh Y; Yarden Y; Johnsen SA; Vojtesek B; Berger SL; Oren M
Genes Dev; 2008 Oct; 22(19):2664-76. PubMed ID: 18832071
[TBL] [Abstract][Full Text] [Related]
28. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.
Monroe SC; Jo SY; Sanders DS; Basrur V; Elenitoba-Johnson KS; Slany RK; Hess JL
Exp Hematol; 2011 Jan; 39(1):77-86.e1-5. PubMed ID: 20854876
[TBL] [Abstract][Full Text] [Related]
29. Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia.
Yamagata K; Shino M; Aikawa Y; Fujita S; Kitabayashi I
Leukemia; 2021 Oct; 35(10):2840-2853. PubMed ID: 33967269
[TBL] [Abstract][Full Text] [Related]
30. Activation of the Lysosome-Associated Membrane Protein LAMP5 by DOT1L Serves as a Bodyguard for MLL Fusion Oncoproteins to Evade Degradation in Leukemia.
Wang WT; Han C; Sun YM; Chen ZH; Fang K; Huang W; Sun LY; Zeng ZC; Luo XQ; Chen YQ
Clin Cancer Res; 2019 May; 25(9):2795-2808. PubMed ID: 30651276
[TBL] [Abstract][Full Text] [Related]
31. Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
Yuan Y; Du L; Tan R; Yu Y; Jiang J; Yao A; Luo J; Tang R; Xiao Y; Sun H
J Med Chem; 2022 Jun; 65(11):7770-7785. PubMed ID: 35612819
[TBL] [Abstract][Full Text] [Related]
32. SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation.
Ropa J; Saha N; Hu H; Peterson LF; Talpaz M; Muntean AG
Haematologica; 2020 Sep; 105(9):2273-2285. PubMed ID: 33054052
[TBL] [Abstract][Full Text] [Related]
33. An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in
Wang H; Shah CA; Hu L; Huang W; Platanias LC; Eklund EA
J Biol Chem; 2020 Jul; 295(28):9663-9675. PubMed ID: 32467231
[TBL] [Abstract][Full Text] [Related]
34. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.
Jo SY; Granowicz EM; Maillard I; Thomas D; Hess JL
Blood; 2011 May; 117(18):4759-68. PubMed ID: 21398221
[TBL] [Abstract][Full Text] [Related]
35. Misguided transcriptional elongation causes mixed lineage leukemia.
Mueller D; García-Cuéllar MP; Bach C; Buhl S; Maethner E; Slany RK
PLoS Biol; 2009 Nov; 7(11):e1000249. PubMed ID: 19956800
[TBL] [Abstract][Full Text] [Related]
36. RE-IIBP Methylates H3K79 and Induces MEIS1-mediated Apoptosis via H2BK120 Ubiquitination by RNF20.
Woo Park J; Kim KB; Kim JY; Chae YC; Jeong OS; Seo SB
Sci Rep; 2015 Jul; 5():12485. PubMed ID: 26206755
[TBL] [Abstract][Full Text] [Related]
37. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
[TBL] [Abstract][Full Text] [Related]
38. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia.
Risner LE; Kuntimaddi A; Lokken AA; Achille NJ; Birch NW; Schoenfelt K; Bushweller JH; Zeleznik-Le NJ
J Biol Chem; 2013 Oct; 288(41):29901-10. PubMed ID: 23990460
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias.
Banday S; Farooq Z; Ganai SA; Altaf M
Clin Epigenetics; 2020 May; 12(1):73. PubMed ID: 32450905
[TBL] [Abstract][Full Text] [Related]
40. Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia.
Richter WF; Shah RN; Ruthenburg AJ
Elife; 2021 Jul; 10():. PubMed ID: 34263728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]